The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS‐123 on Mantle cell lymphoma

@article{Li2018TheMK,
  title={The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS‐123 on Mantle cell lymphoma},
  author={J. Li and X. Wang and Y. Xie and Z. Ying and W. Liu and L. Ping and C. Zhang and Z. Pan and N. Ding and Y. Song and J. Zhu},
  journal={International Journal of Cancer},
  year={2018},
  volume={142}
}
  • J. Li, X. Wang, +8 authors J. Zhu
  • Published 2018
  • Biology, Medicine
  • International Journal of Cancer
  • Mantle cell lymphoma (MCL) is an aggressive and incurable malignant disease. Despite of general chemotherapy, relapse and mortality are common, highlighting the need for the development of novel targeted drugs or combination of therapeutic regimens. Recently, several drugs that target the B‐cell receptor (BCR) signaling pathway, especially the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicate that… CONTINUE READING
    12 Citations
    The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
    • 4
    Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro
    • 2
    • PDF
    Revisiting mTOR inhibitors as anticancer agents.
    • 6
    P21-activated kinase 7 (PAK7) interacts with and activates Wnt/β-catenin signaling pathway in breast cancer
    • 13
    • PDF
    Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients
    • 1
    lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR
    • 11

    References

    SHOWING 1-10 OF 53 REFERENCES
    Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
    • 42
    • PDF
    Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma
    • 54
    • PDF
    Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    • 1,076
    • PDF
    A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    • 278
    • Highly Influential
    • PDF